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Abstract
Purpose—To determine whether systematic differences were present between myocardial R2* 
values obtained with two different decay models: truncation and exponential-plus-constant (Exp-
C).
Methods—Single-center cohorts were used to compare black and bright blood sequences 
separately and a multi-center cohort of mixed bright and black blood studies was used to assess 
the generalizability. Truncated exponential estimates were calculated with CMRTools that uses a 
single region of interest (ROI) method. Exp-C estimates were calculated using a pixelwise 
approach.
Results—No differences could be distinguished based upon whether a white or black blood 
sequence was examined. The two fitting algorithms gave similar R2* values, with R-squared 
values exceeding 0.997 and CoV of 3–4%. Results using the pixelwise method yielded a small 
systematic bias (~3%) that became apparent in patients with severe iron deposition. This disparity 
disappeared when Exp-C fitting was used on a single ROI suggesting that the use of pixelwise 
mapping was responsible for the bias. In the multicenter cohort the strong agreement between the 
two fitting approaches was reconfirmed.
Conclusion—Cardiac R2* values are independent of the signal model used for its calculation 
over clinically relevant ranges. Clinicians can compare results among centers using these disparate 
approaches with confidence.
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Estimation of myocardial iron stores is essential for preventing cardiac disease and 
managing chelation treatment in patients with thalassemia, sickle cell disease, aplastic 
anemia, myelodysplasia, and other iron-related diseases (1,2). Cardiovascular magnetic 
resonance (CMR) is noninvasive and clinically validated for this purpose (3,4). Iron causes 
the darkening of gradient-echo CMR images and the rate of darkening (R2*) is proportional 
to the tissue iron content (5); the inverse of R2*, called T2*, is also commonly used to 
characterize cardiac iron burden.
The R2* value is obtained by fitting the CMR signal at different echo times (TEs) to an 
appropriate decay model. In heavily iron-overloaded hearts, the rapid signal loss leads to a 
plateau in the signal decay curve at later echo times. In this situation, fitting a simple mono-
exponential model to all of the echo times produces large R2* underestimation errors (6,7). 
Two approaches are used to resolve this problem. The first approach (truncation model) 
consists of manually limiting the mono exponential equation to a few echo times. 
Measurements are calculated from a full-thickness septal region of interest (ROI). This 
approach has been implemented within different validated softwares: the CMRTools 
(Cardiovascular Imaging Solutions Ltd, London, UK), used firstly by the Pennell’s group 
(7,8) and acquired by different CMR centers worldwide (9,10), the HIPPO MIOT®, used by 
the 8 CMR centers of the Myocardial Iron Overload in Thalassemia (MIOT) Network 
(11,12), and the CMR42 (Circle Cardiovascular Imaging, Canada). The second approach 
consists in fitting the signal with an exponential plus a constant offset. R2* values are 
calculated from every pixel in the interventricular septum and the median R2* is reported. It 
is advocated by some, including our laboratory (6), and recently has been independently 
implemented in an open-source software (13).
It is important for patient management that the calculated R2* values (or T2* values) are 
independent from the software used. Two prior reports suggested that large differences may 
exist (7,14). Thus we compared cardiac R2* values using the two fitting models in two 
disparate patient populations to determine whether systematic differences were evident.
METHODS
Study population
Two single-center cohorts and one multi-center cohort of patients were considered. The first 
single-center cohort included 42 patients (24 with thalassemia major, 13 with sickle cell 
disease, and 5 with other iron-related diseases) scanned using a black blood T2* technique. 
Mean age was 19.3 ± 10.1 years and 21 patients were females. The second single-center 
cohort included 70 patients (31 with thalassemia major, 21 with sickle cell disease, and 18 
with other iron-related diseases) scanned using a white-blood T2* technique. Mean age was 
18.7 ± 10.9 years and 30 patients were females. Our thalassemia cohort is 24% Chinese, 
20% other Southeast Asia (Vietnamese, Laotian, Cambodian, Thai, Filipino), 17% Indian 
Subcontinent (Indian, Pakastani), 23% Mediterranean (Italian, Greek, Cypriot), 9% Middle 
Eastern (Iranian, Lebanese, Iraqi, Saudia Arabia) and 4.5% Hispanic and 2.5% other ethnic 
backgrounds. Our sickle cell disease cohort is 95% African descent and 5% Hispanic.
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Multicenter data represented baseline measurements from a phase II clinical trial of 
FBS0701 (15). These data were used as a test set because they were collected according to 
local, clinical practice from eight major thalassemia centers. Half of the centers used white-
blood acquisitions and half used black-blood techniques. Sixty-two patients of mixed race 
(17 Asian, 5 Black, 5 Thai and 35 White) participated with sites contributing between four 
and thirteen examinations (median, seven cases). Thirty patients were females and mean age 
was 27.9 ± 8.9 years. Fifty-eight patients suffered from thalassemias and 4 from sickle cell 
disease and all were regularly transfused and chelated.
The distribution of the patients is reported in Table 1.
The protocol was approved by The Children’s Hospital of Los Angeles’ Committee for the 
Protection of Human Subjects (Protocol # CCI-12-00087) and the institutional review 
boards of all participating hospitals. The requirement for consent was waived for the 
retrospective data analysis. All patients in the prospective FBS0701 trial gave written 
informed consent.
MRI Acquisition
Both single-center cohorts underwent CMR at the Children’s Hospital of Los Angeles 
(CHLA), but using two different 1.5T scanners: a Philips Achieva (Philips Medical Systems, 
Best, The Netherlands) running system 2.5.1 and a GE Signa CVi (GE Healthcare, 
Waukesha, WI) running system 9.1; similar phased array torso coils were used on both. 
Black blood multiecho gradient echo images were used to calculate R2* on the Philips while 
bright blood multiecho gradient echo R2* sequence was used on the GE scanner.
For the multi-center cohort gradient echo images were acquired on 1.5T scanners from all 3 
major MR vendors. Black or bright blood acquisitions were used (Figure 1).
At the CHLA as well as in all the other sites a single short axis mid-ventricular slice was 
acquired. All R2* sequence parameters are indicated in Table 1.
R2* measurement
All images were processed by the same operator. Identical regions of interest (ROI’s) were 
drawn in the mid-ventricular septum for both techniques. Truncated exponential estimates 
were calculated using CMRTools. It calculates the mean signal intensity of the ROI for each 
image and fits the decay curve to a mono-exponential model:
[1]
where S=fitted signal, S0=initial amplitude, TE=echo time. The R-square value describing 
the goodness of fitting was used by the operator as guide in the application of the truncation 
model. If the R-square value was > 0.99, no truncation was applied. Otherwise, the last 
points were discarded in succession until the R-square value became > 0.99. Finally, the R2* 
value was calculated as 1000/T2*.
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Exponential + constant (Exp-C) estimates were calculated using a rapid pseudo-pixelwise 
implementation written in MATLAB (The Mathworks, Natick, MA). This software, called 
Iron, divides the ROI into subregions of similar-relaxivity; the number of pixels in each 
subregion is equal to the square-root of the total number of pixels in the traced ROI. Each 
subregions is fitted to a Exp-C model:
[2]
where S=fitted signal, S0=initial amplitude, TE=echo time, R2* is the relaxivity, and C is 
the constant offset term. A distribution of R2* values is produced and the mean and median 
from this distribution are obtained (16). We also implemented equation 2 over the entire 
ROI, similar to CMRTools, to distinguish whether differences in measured R2* values 
resulted from the underlying fitting model (equations 1 and 2) or from the use of a pixelwise 
rather than a region-based approach.
Hereafter we refer to the R2* values obtained with the CMRTools as R2*CMRTools and to 
the R2* values obtained using Iron as R2*Iron-mean (mean of R2* distribution taken into 
account), R2*Iron-median (median of R2* distribution taken into account) and 
R2*Iron_ROI_based (single ROI).
Statistical analysis
All data were analyzed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) and 
MedCalc for Windows version 7.2.1.0 (MedCalc Software, Mariakerke, Belgium) statistical 
packages.
Continuous variables were described as mean ± standard deviation (SD).
Summary data were displayed using scatter plots with regression lines. Linear regression 
models provided slope and intercept estimates and the R-squared measuring the goodness of 
the linear fit. Because R2* values were not normally distributed, a paired Wilcoxon signed 
rank test was applied to detect significant differences between two datasets while the 
Spearman correlation coefficient was used to assess their relationship. A coefficient of 
variation (CoV) was calculated as the ratio of the SD of the half mean square of the 
differences between the repeated values, to the general mean. The Bland-Altman (BA) 
technique was used to plot the absolute difference (standard BA) or the percent difference 
(relative BA) versus the average values between two datasets. The relative Bland-Altman 
plot was preferred when the variability of the differences increased as the magnitude of the 
measurements increased. Bias was the mean of the difference between the two methods and 
agreement was the mean ± 1.96 SDs.
A P value < 0.05 was considered statistically significant.
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First single-center cohort: black blood images
Figure 2a (left) shows R2*Iron-mean values as a function of R2*CMRTools values. The line of 
best fit had a slope of 1.031 ± 0.005, significantly different from 1 (P<0.0001), and an 
intercept of −1.176 ± 0.379 Hz. The R-squared value for the fit was 0.999. The R2*Iron-mean 
values were not significantly different from R2*CMRTools values (48.5 ± 54.7 Hz vs 48.2 ± 
53.1 Hz, P=0.945). Bland-Altman analysis demonstrated no significant bias between the two 
techniques, with limits of agreement of 4.8 Hz (Figure 2a, right). The CoV was 3.5%.
Relationships between R2*Iron-median and R2*CMRTools as well between R2*Iron-ROI_based 
and R2*CMRTools was nearly identical to results for R2*Iron-mean, being well described by a 
straight line. In both cases Bland-Altman analysis demonstrated good agreement and the 
CoV was less than 4.4% (Table 2a).
Second single-center cohort: bright blood images
Figure 2b (left) shows R2*Iron-mean values as a function of R2*CMRTools values. The line of 
best fit had a slope of 1.025 ± 0.005, significantly different from 1 (P<0.0001), and an 
intercept of −0.741 ± 0.300 Hz. The R-squared value for the fit was 0.998. The R2*Iron-mean 
values were not significantly different from R2*CMRTools values (47.6 ± 37.9 Hz vs 47.2 ± 
36.9 Hz, P=0.088). Bland Altman analysis demonstrated no significant bias between the two 
techniques, with limits of agreement of 3.5 Hz (Figure 2b, right). a trend toward higher 
values using the Exp-C method The CoV was 2.7%.
The results of the comparison between R2*Iron-median and R2*CMRTools and between 
R2*Iron-ROI_based and R2*CMRTools are indicated in Table 2b. In both cases a strong linear 
relationship was demonstrated, the Bland-Altman analysis demonstrated no significant bias 
and the CoV was less than 3.5%.
Multi-center cohort
Figure 2c (left) shows R2*Iron-mean values as a function of R2*CMRTools values. The line of 
best fit had a slope of 0.989 ± 0.008, not significantly different from 1 (P=0.148), and an 
intercept of 0.108 ± 0.372 Hz. The R-squared value for the fit was 0.997. The R2*Iron-mean 
values were not significantly different from R2*CMRTools values (43.5 ± 22.6 Hz vs 43.8 ± 
22.7 Hz, P=0.250). The CoV was 2.3%. Figure 2c (right) shows the Bland-Altman plot.
The results of the comparison between R2*Iron-median and R2*CMRTools and between 
R2*Iron-ROI_based and R2*CMRTools are indicated in Table 2c. In both cases a strong linear 
relationship was found out and the CoV was under 2.3%.
Patients with cardiac iron
As can be inferred from the both the linear regression analysis and Bland-Altman plots, the 
pixelwise, Exp-C analysis yields slightly higher values at larger R2*s. To better characterize 
that effect for an acceptable number of patients (N=45), we pooled all patients with 
detectable cardiac iron (R2*CMRTools ≥ 50 Hz). Figure 3 shows the relative Bland-Altman 
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plots for this subgroup of patients for pixel-wise mean, pixel-wise median, and region-based 
application of the Exp-C model. No significant bias was detected in all three metrics. Five 
patients had T2* < 6 ms. In these patients, the pixelwise mean and median (Figure 3a and 
3b) was 3% higher than predicted by CMR Tools but this disparity disappeared when a 
global ROI was used (Figure 3c).
DISCUSSION
In the last years, CMR R2* has become a widely used accurate and noninvasive technique 
for monitoring heart iron overload in patients with different types of hemoglobinopathies 
(17,18). Potential sources of variability include image acquisition parameters and image 
analysis methods. A number of different studies have shown that this technique is 
transferable between MRI scanners in different centers (12) and from different 
manufacturers (8,19). A number of approaches are used for calculating cardiac R2* from the 
source images. Within these approaches, there is generally good intra- and inter-observer 
reproducibility for both bright blood (20) and black blood T2* CMR (21). However, some 
had reported large differences in R2* results based upon a truncated exponential fit versus 
fitting to an exponential with a constant offset (7,14), warranting a independent, systematic 
comparison of the two approaches.
In all three patient cohorts, we observed that the two fitting approaches yield similar R2* 
values with R-squared values exceeding 0.997, regardless of whether white or black blood 
images were used. More importantly, the CoV was extremely low, suggesting excellent 
stability of both techniques. Nonetheless, the regression slopes were ~3% greater than unity 
and these differences became more apparent in patients with severe iron deposition (R2* > 
100 Hz). This is in agreement with two previous studies involving the liver. Beaumont et al. 
showed that in the liver the models differences became evident for R2* values higher than 
200 Hz (22). Meloni et al. demonstrated that the relationship between hepatic R2*Iron-median 
and R2*CMRTools values was well described by a line and that results were unbiased for 
R2*<300 Hz, but large systematic differences in R2* appeared at higher values, with the 
exponential-plus-constant fits averaging ~20% higher (23). The biases arise from two 
sources, use of pixel-wise mapping rather than a region-based technique as well as the 
underlying relaxation model (Equations 1 and 2). Figure 3c suggests that it is the use of 
pixelwise mapping that is responsible for 3% bias, rather than the fitting model. When there 
is high spatial variability of tissue iron distribution, pixelwise mapping more closely reflects 
the true average tissue iron concentration than using a global ROI. Ghugre et al. (6) also 
demonstrated that, using identical signal decay models, pixelwise fits yielded 3–5% higher 
R2* values than a global ROI at high iron concentrations. Regardless of which approach 
more closely approximates true iron concentration, the systematic R2* bias between these 
approaches is so small that it is clinically irrelevant.
We used three different cohorts to probe the differences over as a broad a patient base as 
possible. We could distinguish no differences based upon whether a white or black blood 
sequence was examined. To obtain higher generalizability, we also included a multi-center 
cohort of patients scanned according to the specific protocol of their center using a mixture 
of white and black blood techniques. We reconfirmed the strong agreement between R2* 
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values obtained with the two softwares (Figure 2c). While the study was somewhat 
hampered by small number of patients having cardiac iron in any single cohort, the pooled 
sample size (N=45) was large enough to detect any significant systematic deviation. Our 
study might have been able to detect larger differences if our study populations included 
more patients with cardiac T2* < 5 ms, but such patients are becoming rare at institutions 
performing routine cardiac screening because diagnosis triggers intensified therapy and they 
tend to present with heart failure or death at centers lacking MRI screening. Since the 
therapy of any patient whose T2* is < 5 ms should be maximally escalated, our current data 
completely spans the clinically-relevant range. Furthermore our data from liver suggest the 
maximum error is < 15% and is detectable only when T2* falls below 3 ms (23). We cannot 
explain why we were unable to replicate the findings of He et al (7), however the lack of 
systematic bias explains why our initial in-vitro calibration curve (4) agrees closely with 
more recent data analyzed using CMRTools (18).
In conclusion, we showed that the cardiac R2* values are independent of the signal model 
(Equation 1 or 2) used for its calculation. Software using a pixel-wise approach will yield 
R2* values approximately 3% greater than for a region-base approach in severely iron 
overloaded subjects, similar to prior simulations (6). The overall variability among these 
techniques is exceeding small and negligible clinically. Thus, it is not likely to significantly 
affect clinical management or indeed lead to inappropriate management of patients. 
Moreover, clinicians can compare results with confidence among centers using these 
disparate approaches.
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Typical black blood (left) and bright blood (right) short-axis mid-ventricular images at the 
first echo time.
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Comparison between R2*Iron-mean values and R2*CMRTools values for a) the first single-
center cohort (black blood images), b) the second single-center cohort (bright blood images) 
and c) the multi-center cohort. Left: Scatter plot with regression line (solid line). The dotted 
line is the line of identity. Right: Bland-Altman plot of absolute differences. Dotted lines 
indicate the limits of agreement.
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Agreement between the two methods for all patients with detectable cardiac iron. Relative 
Bland-Altman plots for a) R2*Iron-mean and R2*CMRTools values, b) R2*Iron-median and 
R2*CMRTools values and c) R2*Iron-ROI_based and R2*CMRTools values.
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